SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
Alexander BiederstädtUlrich Bernd KellerChristian SchneeweisMarkus SchickLara SchneiderAlexander MuckenhuberYingfen HongGerrit SiegersLisa NilssonMatthias WirthZahra DantesKatja SteigerKathrin SchunckSteve LangstonH-P LenhofAndrea ColuccioFelix OrbenJolanta SlawskaAnna SchergerDieter SaurStefan MüllerRoland RadWilko WeichertJonas NilssonMaximilian ReichertGünter SchneiderPublished in: Gut (2020)
SUMO inhibitor-based therapies should be further developed for an aggressive PDAC subtype.
Keyphrases